Biocon Ltd has lined up products in new therapies such as glaucoma/eye-care. It plans to enter the lucrative and growing segment of ophthalmology through synthetic prostaglandins that are used to treat glaucoma, among other problems.
Branded formulations, a new range of injectable APIs (basic or active pharma ingredients) and peptides or proteins developed out of complex molecules will join the portfolio through two new divisions, the company said in its latest annual report. This year, it will add Comprehensive Care and Immuno Therapy divisions to the four divisions that currently have 36 brands.
With the commercialisation of synthetic prostaglandins used in the treatment of glaucoma, Biocon will make its foray into ophthalmics. The new product range includes synthetic prostaglandins, injectable APIs and peptides, several of which are niche molecules where the technology involved is complex and challenging.
With prostaglandin that lowers the fluid pressure in the eye, Biocon would be entering a zone where Allergan, Cipla, Sun Pharma, Bangalore-based Micro Labs and Novartis/Alcon are present. The glaucoma segment, according to an industry source, was around Rs 108 crore last year and is growing at 37 per cent annually.
Last year, the Glaucoma Society of India said 12 million people in
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1483.75 |
| Dr. Reddys Lab | 5947.30 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 958.90 |
| Lupin | 1580.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
